Article Text

OP0224 Anti-AT1R and Anti-ETAR Autoantibodies from Patients with SSC and their Agonistic Effects
  1. A. Kill1,
  2. J. Günther1,
  3. M. O. Becker1,
  4. D. Dragun2,
  5. G.-R. Burmester1,
  6. G. Riemekasten1
  1. 1Rheumatology and clinical Immunology
  2. 2Nephrology, Transplantology and Intensive Care, Charité-University Hospital Berlin, Germany, Berlin, Germany


Background Autoantibodies reactive to angiotensin II type 1 receptor (AT1R) and endothelin 1 type A receptor (ETAR), anti-AT1R and anti-ETAR autoantibodies, are found in patients with Systemic sclerosis (SSc) as a prototypic connective tissue disease with limited therapeutic options. SSc is characterized by three major hallmarks: autoimmunity, vasculopathy and fibrosis. Anti-AT1R and anti-ETAR autoantibodies (Ab) have been demonstrated in association with clinical symptoms of SSc including vascular and fibrotic complications. Therefore, direct agonistic effects of anti-AT1R and anti-ETAR Ab were studied.

Objectives To analyse anti-AT1R and anti-ETAR Ab-mediated agonistic effects in in vitro and in vivo experimental settings.

Methods Human microdermal endothelial cells-1 (HMEC-1) were treated with IgG from SSc patients positive for anti-AT1R and anti-ETAR Ab, or with IgG of healthy donors (NC-IgG). To demonstrate angiotensin- and/or endothelin-receptor activation, cells were pre-treated with specific receptor inhibitors, either alone or in combination. Cell activation was measured by IL-8 chemokine expression, adhesion molecule VCAM-1 expression, trans-endothelial neutrophil migration and ROS activation using qRT-PCR, sandwich ELISA, cell culture inserts and fluorescence analysis. In vivo effects were measured by autoantibody transfer into healthy C57Bl/6J mice and analysis of cellular BALF composition.

Results Upon treatment with anti-AT1R and anti-ETAR Ab positive SSc-IgG, HMEC-1 cells increased IL-8 mRNA levels and IL-8 protein secretion into culture supernatants compared to cells treated with NC-IgG. Levels of IL-8 mRNA and protein were decreased in samples that were pre-treated with specific angiotensin- and endothelin-receptor blockers. Culture supernatants with increased IL-8 protein levels due to SSc-IgG treatment, showed an increased potential to recruit neutrophils through an endothelial cell layer, compared to supernatants of NC-IgG treated samples. Again, specific angiotensin- and endothelin-receptor inhibition showed a reduction in neutrophil recruitment. Culture supernatants conditioned with SSc-IgG increased reactive oxygen species (ROS) production in healthy donor neutrophils compared to supernatants with control treatment. Furthermore, HMEC-1 cells showed also increased mRNA levels of VCAM-1 with significant reduction by receptor inhibition. Moreover, mice that received anti-AT1R and anti-ETAR Ab positive SSc-IgG showed significantly increased neutrophil number in BALF compared to NC-IgG.

Conclusions Our findings demonstrate the potential of anti-AT1R and anti-ETAR Ab to induce pathogenic effects in vitro and in vivo. Activation of endothelial cells by anti-AT1R and anti-ETAR Ab might reflect in some aspects the situation as seen in vivo and could thereby be an important factor in disease pathogenesis. Furthermore, cell activation by these autoantibodies induced neutrophil recruitment in vitro. Finally, activation of neutrophil recruitment by anti-AT1R and anti-ETAR Ab positive SSc-IgG, demonstrated the potential to directly induce pathogenic effects in healthy mice in vivo. Thus, angiotensin- and endothelin-receptor activation by anti-AT1R and anti-ETAR Ab could significantly contribute to pathogenesis of SSc.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.